Latest News and Press Releases
Want to stay updated on the latest news?
-
MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia ...
-
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
-
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
-
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the...
-
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
-
Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD...
-
Clarivate will monitor, manage, and maintain Company’s expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
-
Study data to determine potential delivery partners ENGLEWOOD CLIFFS, NJ, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical...
-
ENGLEWOOD CLIFFS, NJ, June 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
-
Initial indications are fibromyalgia and chronic pain ENGLEWOOD CLIFFS, NJ, June 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...